| HOME >> BIOLOGY >> TECHNOLOGY |
New Facility Meets LEEDS Standards for Sustainable Development
PLEASANTON, Calif., April 3, 2008 /PRNewswire/ -- Roche Molecular Diagnostics (RMD) today announced the opening of its new research facility at the company's global headquarters in Pleasanton, California. The building represents the final phase of consolidation of RMD's West Coast operations into one campus in Pleasanton which now houses close to 500 employees, including 120 members of RMD's research teams previously located in Alameda. RMD is a world-leading molecular diagnostics company, developing diagnostics designed to provide information allowing healthcare providers to select and monitor patient response to therapy or identify molecular characteristics of a disease. RMD's products also help to ensure the safety of blood and blood products before they are used for medical procedures by using its approved systems to screen donations.
RMD is a world-leading molecular diagnostics company, developing diagnostics that provide information to select the best therapy for a particular patient by enabling physicians to monitor response to treatment or identify molecular characteristics of a disease. RMD also supports the safety of the blood supply by using our approved systems to screen donors.
The research building encompasses more than 135,000 square feet on
RMD's 33.4 acre campus in the Hacienda Business Park. Designed by a local
firm, DES Architects + Engineers under the leadership of Craig Ivancovich,
architect and principal, it was then built by another local company, DPR
Construction. The building and its surroundings incorporate numerous
features designed to ensure successful green building status, construction
and operation, and further demonstrate Roche's ongoing commitment to
sustained development and environmental efficiency throughout its global
operations. Going forward, RMD is working to implement final operational
improvements that will enable the new facility t
'/>"/>
| SOURCE Roche Molecular Diagnostics Copyright©2008 PR Newswire. All rights reserved |